TCON: Multiplikator P/S TRACON
TRACON Pharmaceuticals management is finalizing asset liquidation following the suspension of core programs, which is directly impacting the share price. The market cap-to-revenue ratio demonstrates volatility, with the current level standing at 0.00. The company previously relied on low molecule testing costs and inelastic demand in oncology, while simultaneously implementing energy saving and safe chemical disposal in its laboratories.
Rincian analitis perusahaan TRACON (TCON)
- rega saham lan konsensus proyeksi valuasi:
- informasi kapitalisasi pasar:
- data ekuitas miturut neraca:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal TRACON Pharmaceuticals|TCON - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas TRACON Pharmaceuticals, Inc|TCON - Gunggung utang perusahaan|Utang-utang marang nilai buku TRACON|TCON - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan TRACON Pharmaceuticals|Rasio likuiditas perantara traconpharma.com
- informasi bathi lan kelipatan valuasi:
TCON - Bathi resik|Prakiraan bathi perusahaan TRACON Pharmaceuticals|TCON - Pangali P/E|Prakiraan rega marang bathi TRACON Pharmaceuticals Inc.|TCON - Pangali PEG|Pangali EV/EBITDA TRACON|TCON - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan TRACON Pharmaceuticals|TCON - Bathi saben saham sajrone rolas wulan pungkasan|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan traconpharma.com|TCON - Wutah bathi resik saben saham ing taun iki|Proyeksi tambahing bathi saben saham ing taun ngarep TRACON Pharmaceuticals
- data total pendapatan lan volume dodolan:
Analisis umum perusahaan:TCON - traconpharma.com
Low fundamental multiples in this case do not signal undervaluation, but rather reflect a critical breakdown of the business model. Analyzing the enterprise value-to-revenue ratio, an investor sees the market valuation of every dollar of sales, which for TRACON Pharmaceuticals (TCON) is plummeting amid failed clinical trials and a genuine threat of total liquidation.
Karo sapa TRACON Pharmaceuticals saingan
TEM (Tempus AI) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S QGEN (Qiagen)|Multiplikator P/S Ionis Pharmaceuticals, Inc. IONS|RGEN - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan RNA (Avidity Corp)|CRISPR Therapeutics AG (CRSP) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan genedx.com|RARE (Ultragenyx) - Multiplikator P/S|Multiplikator P/S Beam Therapeutics Inc|Multiplikator P/S SRPT|Kapitalisasi marang pendapatan Twist Bioscience Corp TWST|Multiplikator P/S TXG (10x Genomics, Inc.)|intelliatx.com (NTLA) - Rega marang dodolan|STOK: Kapitalisasi marang pendapatan|BLFS - Multiplikator P/S|WVE (Wave Life Sciences Corp) - Kapitalisasi marang pendapatan|MAZE: Kapitalisasi marang volume dodolan|SION (Sionna Therapeutics Inc) - Multiplikator P/S|primemedicine.com (PRME) - Koefisien rega marang pendapatan|Multiplikator P/S TSHA|Kapitalisasi marang pendapatan uniQure NV QURE|Multiplikator P/S MGTX (MeiraGTx PLC)|Multiplikator P/S REGENXBIO Corp RGNX|SLDB - Rasio rega marang pendapatan|OCGN: Rasio rega marang pendapatan|PacBio (PACB) - Rasio rega marang pendapatan|BNTC - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan DSGN|RCKT (Rocket Corp) - Kapitalisasi marang volume dodolan|Multiplikator P/S FDMT|Kapitalisasi marang pendapatan lexeotx.com LXEO|Rasio rega marang pendapatan Korro Bio KRRO|Editas Medicine Inc (EDIT) - Rega marang dodolan|SLN - Rasio rega marang pendapatan|PRQR (ProQR Therapeutics N.V.) - Rasio kapitalisasi marang pendapatan|CDXS: Multiplikator P/S|Rasio kapitalisasi marang pendapatan SGMO|Rasio rega marang pendapatan Nautilus Biotechnology, Inc.|Rasio kapitalisasi marang pendapatan MGX (Metagenomi Inc.)|Multiplikator P/S DTIL|Multiplikator P/S generationbio.com (GBIO)|Boundless Bio, Inc. - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan XCUR (Exicure Inc.)|IMNN - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan PHIO (Phio Pharmaceuticals)|MBIO: Multiplikator P/S|TransCode Therapeutics, Inc. (RNAZ) - Multiplikator P/S|BNGO (Bionano Genomics Inc.) - Multiplikator P/S|Kapitalisasi marang pendapatan adnas.com (APDN)|Rasio rega marang pendapatan bluebird bio (BLUE)|IPA - Rega marang dodolan|Rasio rega marang pendapatan Omega OMGA|OMIC: Rasio kapitalisasi marang pendapatan|RGLS: Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan SYRS (syros.com)|Telesis Bio (TBIO) - Rasio rega marang pendapatan|Rasio rega marang dodolan UBX (Unity Biotechnology Inc.)
